Lawson Kroeker Investment Management Inc. NE Sells 80,550 Shares of Bruker Corporation $BRKR

Lawson Kroeker Investment Management Inc. NE lowered its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 38.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 131,535 shares of the medical research company’s stock after selling 80,550 shares during the quarter. Bruker accounts for about 1.8% of Lawson Kroeker Investment Management Inc. NE’s portfolio, making the stock its 23rd largest position. Lawson Kroeker Investment Management Inc. NE’s holdings in Bruker were worth $6,197,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Sector Gamma AS lifted its holdings in shares of Bruker by 28.0% in the 3rd quarter. Sector Gamma AS now owns 250,909 shares of the medical research company’s stock valued at $8,152,000 after acquiring an additional 54,939 shares during the last quarter. Becker Capital Management Inc. increased its stake in Bruker by 606.8% during the third quarter. Becker Capital Management Inc. now owns 301,155 shares of the medical research company’s stock worth $9,800,000 after acquiring an additional 258,545 shares during the last quarter. DNB Asset Management AS raised its position in Bruker by 40.5% during the third quarter. DNB Asset Management AS now owns 143,257 shares of the medical research company’s stock valued at $4,654,000 after purchasing an additional 41,289 shares during the period. Aquatic Capital Management LLC raised its position in Bruker by 120.3% during the third quarter. Aquatic Capital Management LLC now owns 349,596 shares of the medical research company’s stock valued at $11,358,000 after purchasing an additional 190,883 shares during the period. Finally, M&G PLC lifted its stake in shares of Bruker by 233.0% in the 3rd quarter. M&G PLC now owns 1,096,226 shares of the medical research company’s stock valued at $35,079,000 after purchasing an additional 766,992 shares during the last quarter. 79.52% of the stock is owned by hedge funds and other institutional investors.

Bruker Stock Performance

BRKR opened at $36.76 on Friday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The stock’s 50 day moving average price is $38.60 and its 200-day moving average price is $41.31. Bruker Corporation has a one year low of $28.53 and a one year high of $56.22. The stock has a market cap of $5.60 billion, a price-to-earnings ratio of -245.07, a P/E/G ratio of 2.20 and a beta of 1.20.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The business had revenue of $977.20 million for the quarter, compared to the consensus estimate of $964.61 million. During the same period in the prior year, the business posted $0.76 earnings per share. Bruker’s revenue was down .2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts forecast that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be paid a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Monday, March 23rd. Bruker’s payout ratio is currently -133.33%.

Analysts Set New Price Targets

A number of brokerages have recently commented on BRKR. Citigroup dropped their target price on Bruker from $53.00 to $40.00 and set a “neutral” rating for the company in a report on Friday, February 13th. Barclays lowered their price target on Bruker from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. UBS Group reaffirmed a “neutral” rating and set a $49.00 price objective on shares of Bruker in a research note on Friday, February 13th. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a research note on Friday, March 27th. Finally, Wolfe Research upgraded shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price for the company in a report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $49.77.

Insider Activity at Bruker

In other news, VP Mark Munch sold 7,000 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $55.00, for a total value of $385,000.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $7,064,365. This represents a 5.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders have sold 11,000 shares of company stock valued at $554,280 in the last quarter. Corporate insiders own 27.30% of the company’s stock.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.